Table 3.
Type of sample | Procedure | Minimum process volume required | Container | At time | Place of analysis | Storage | Shipment | Destructionh |
---|---|---|---|---|---|---|---|---|
Venous or finger/heel prick whole blood or plasma | HIV 1–2 RT-PCR POC automated nucleic acid testing platform (ALERE®) | 0.3 ml | Cartridge/ | Yes | Locally | No | No | According to manufacturer |
Capillary/ | ||||||||
EDTA | ||||||||
Venous whole blood | Total blood count Automatic coulter | 0.5 ml | EDTA | Yes | Locally | No | No | |
Venous whole blood | ALT, Creatinine, Glucose | 0.5 ml | Dry tube | Yes | Locally | No | No | |
Automatic analyzer | ||||||||
Venous whole blood | CD4 (absolute number and %) | 0.2 ml | EDTA | Yes | Locallye | No | No | |
Venous whole blood | HIV viral load | 1 ml | EDTA | Yes | Locallye | No | No | |
NPAa | Xpert MTB/RIF Ultra (TB PCR) | 2–5 ml | Mucus extractor | Yes | Locally | No | No | According to manufacturer |
Stools | Xpert MTB/RIF Ultra (TB PCR) | 5 g | Stools container | Yes | Locally | No | No | According to manufacturer |
Urine | Fujifilm TB LAM | 5 ml | Urine container | Yes | Locally | No | No | According to manufacturer |
Venous whole bloodf | CMV viral load | 1 ml | EDTA | No | Zambia | − 80 °C+/− 10 °C, | Only DNA ambient | |
Salivaf | CMV viral load | Swab | Universal Transport Medium | No | Zambia | −80 °C+/− 10 °C | Only DNA ambient | |
Sub-study and ancillary tests | ||||||||
Venous whole bloodb | PK1:t = 0, 2, 4, 6, 8, and 12 h after intake | 1 ml each | Heparin | No | NTL | −80 °C+/− 10 °C | Dry ice | |
Venous whole bloodb | PK2: t = 0, 2, 4, 6, 8, 12/24 h after intake | 0.5 ml each | EDTA | No | NTL | −80 °C+/− 10 °C | Dry ice | |
Venous whole bloodb | PK3: t = 2 and 5 after intake | 1 ml each | Lithium heparin | No | NTL | −80 °C+/− 10 °C | Dry ice | |
Venous whole bloodb | PK4: t = 2 | 0.5 ml | Lithium heparin | No | NTL | −80 °C+/− 10 °C | Dry ice | |
Blood, NPA, CSF and post-mortem tru-cutc | Advanced histopathological and microbiologicalg | 10 ml, 2–5 ml, 10 ml, cylinders | EDTA | No | Spain | −80 °C+/− 10 °C | Dry ice | |
Dry tube | ||||||||
Dry tube | ||||||||
NPAd,f | Cytokine levels | ~ 2.5 ml (mucus + SPS) | Mucus extractor | No | Malawi | −80 °C+/− 10 °C | Dry ice | Following local guidelines |
NPAd,f | CMV viral load, genotyping | ~ 2.5 ml | Dry tube | No | Zambia | −80 °C+/− 10 °C | Dry ice | Following local guidelines |
Abbreviations: RT-PCR real-time polymerase chain reaction, ALT alanine transaminase, SPS saline physiological solution, PCR polymerase chain reaction, CMV cytomegalovirus, POC point of care, NPA nasopharyngeal aspirate, CSF cerebrospinal fluid, TB tuberculosis, EDTA Ethylene-diamine tetra-acetic acid, MTB/RIF Mycobacterium tuberculosis DNA and resistance to rifampicin, LAM lipoarabinomannan, PK pharmacokinetics, NTL The Netherlands
aIn the recruitment visit the NPAs will be performed in one action. In case the infant participates in the ancillary immune study the sample will be shared in 3 aliquots
bSub-study performed only in Uganda, Zambia, and Zimbabwe
cSub-study performed only in Mozambique and Zambia
dAncillary study performed only in Blantyre and Lusaka Hospital in Zambia
eSome sites will send to the national referral laboratories
fLeftovers, in Zambia and Malawi, will be stored and later analyzed by molecular methods to identify potential differential causal pathogens and markers of bacterial and mycobacterial antibiotic resistance
gBassat Q, Castillo P, Martínez MJ et al. Validity of a minimally invasive autopsy tool for the cause of death determination in pediatric deaths in Mozambique: An observational study. PLoS Med. 2017 Jun 20;14(6): e1002317
hAccording to trial SOPs for the sample, local guidelines and according protocol